Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation

NCT00158873 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00158873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00158873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2004
Completion date
Not reported
Enrollment
224
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

sedation